| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/27/2005 | US20050019436 Relieving pain at a body site by administering a dosage of capsaicinoid at the painful site without eliciting an effect outside the discrete location; local anesthetic effect; targeted therapy |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019416 Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| 01/27/2005 | US20050019410 dissolving particles in solvents and then precipitation by mixing the solutions with nonsolvents and spray drying to form microstructure particles; imaging contrast enhancing agents used for medical diagnosis |
| 01/27/2005 | US20050019409 Gastric retention dosage form having multiple layers |
| 01/27/2005 | US20050019408 time-release agents comprising water-swellable matrix cores containing estrogen derivative extracted from animals surrounded by film-forming coatings |
| 01/27/2005 | US20050019407 Composite dosage forms |
| 01/27/2005 | US20050019405 Controlled release composition |
| 01/27/2005 | US20050019394 gelling agents having reduced syneresis and improved breaking strength comprising mixtures of irish moss extracts, starches, soybean proteins and/or hydrocolloids, formed by wetting, then shearing and mixing at elevated temperatures, cooling and grinding; used as thickeners and stabilizer agents |
| 01/27/2005 | US20050019391 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/27/2005 | US20050019389 Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
| 01/27/2005 | US20050019386 In mixture of membrane-forming amphiphiles subjected to high pressure homogenization or ultrasound; contain immunomodulator, cyclosporin, and/or at least one cytokine or polyethylene glycol-cytokines |
| 01/27/2005 | US20050019384 Mixture for transdermal delivery of low and high molecular weight compounds |
| 01/27/2005 | US20050019381 Binding agent which is stable in storage and used for pharmaceutical applications |
| 01/27/2005 | US20050019378 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 01/27/2005 | US20050019376 Containing at least one active ingredient and a confectionery composition such as fat, amorphous sugar glass, or fondant; polarized light transmission; especially for pediatric and geriatric applications |
| 01/27/2005 | US20050019374 Plasticizer, film former, bulking agent, and pH controlling agent; |
| 01/27/2005 | US20050019373 Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof |
| 01/27/2005 | US20050019369 making a suture by modifying an aqueous suspension of a nucleic acid, e.g., by capping, crosslinking, methylation, ethylation, or attachment of a protein, to form a viscous gel, which is extruded to form a filament; optionally adding a biodegradable polymer |
| 01/27/2005 | US20050019367 Continuous release of luteinizing hormone releasing hormone (lh-rh) analogue of leuprorelin, buserelin, triptorelin, and/or goserelin |
| 01/27/2005 | US20050019352 Method for preparing a water/oil/water multiple emulsion |
| 01/27/2005 | US20050019350 Gel emulsions in the form of o/w emulsions having a hydrocolloid content |
| 01/27/2005 | US20050019349 Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| 01/27/2005 | US20050019343 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 01/27/2005 | US20050019330 administering an antibody that specifically binds to the amyloid deposit or a component thereof; can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal; also a novel monoclonal antibody which specifically binds to an epitope within residues 13-28 of A beta |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019274 Biofilm removing agent for removing a biofilm |
| 01/27/2005 | US20050019271 Glycopyrrolate in sustained releae form; antimuscarinic agents |
| 01/27/2005 | US20050019266 Therapeutic ultrasond; imaging vascular plaque; administering contrast agent in aqueous carrier; scanning |
| 01/27/2005 | US20050016926 Mixture of anticancer agents and solvent such as polyethoxylated castor oil ; stability |
| 01/27/2005 | CA2819769A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2533314A1 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 01/27/2005 | CA2533199A1 Reactive polymers and copolymers, method of their preparation and their use |
| 01/27/2005 | CA2533084A1 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition |
| 01/27/2005 | CA2532475A1 Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
| 01/27/2005 | CA2532228A1 Lipid encapsulated interfering rna |
| 01/27/2005 | CA2532093A1 Solid formulation |
| 01/26/2005 | EP1500664A1 Gelatin derivatives and high-molecular micelles comprising the same |
| 01/26/2005 | EP1500427A2 Emulsifier for low-viscosity w/o emulsions, based on partially crosslinked polyglycerin esters of polyhydroxystearic acid. |
| 01/26/2005 | EP1500393A1 Injectable composition containing taxol |
| 01/26/2005 | EP1500389A1 Biofilm removing agent |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499746A1 Method to inhibit cell growth using oligonucleotides |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499630A2 Streptavidin expressed gene fusions and methods of use thereof |
| 01/26/2005 | EP1499628A2 Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499361A1 Novel biomaterials, their preparation and use |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499359A1 Temperature responsive delivery systems |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499353A2 Antibodies that specifically bind to tl5 |
| 01/26/2005 | EP1499351A2 Antibodies that specifically bind to tr2 |
| 01/26/2005 | EP1499347A2 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 01/26/2005 | EP1499346A2 Treatment of type 1 diabetes before and after expression of predisposition markers |
| 01/26/2005 | EP1499335A2 Chimeric hybrid analgesics |
| 01/26/2005 | EP1499333A2 Methods of treating ileus |
| 01/26/2005 | EP1499329A1 Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass |
| 01/26/2005 | EP1499318A2 Peptide deformylase activated prodrugs |
| 01/26/2005 | EP1499304A1 Liquid compositions for soft sustained-release capsules and method for production thereof |
| 01/26/2005 | EP1499303A2 Multi-phase, multi-compartment capsular system |
| 01/26/2005 | EP1499299A2 Microparticle pharmaceutical compositions for intratumoral delivery |
| 01/26/2005 | EP1499298A1 Oral administration form for difficulty soluble basic active ingredients which are applied orally |
| 01/26/2005 | EP1499297A2 Pharmaceutical formulation comprising atorvastatin calcium |
| 01/26/2005 | EP1499294A2 Transport system in biological systems |
| 01/26/2005 | EP1499291A1 Methods and dosage forms for controlled delivery of oxycodone |
| 01/26/2005 | EP1499290A1 Warming and nonirritating lubricant compositions |
| 01/26/2005 | EP1499289A2 Volume efficient controlled release dosage form |
| 01/26/2005 | EP1499204A2 Physiologically compatible, phospholipid-containing, stable and hard matrix |
| 01/26/2005 | EP1499189A1 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1441704B1 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/26/2005 | EP1392751A4 Biodegradable copolymers linked to segment with a plurality of functional groups |
| 01/26/2005 | EP1330237B1 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/26/2005 | EP1320359B1 Thermogelling biodegradable aqueous polymer solution |
| 01/26/2005 | EP1265942B1 Use of poly(diallylamine) polymers |
| 01/26/2005 | EP1233752B1 Radiation sensitive liposomes |
| 01/26/2005 | EP1231926B1 Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
| 01/26/2005 | EP1165091B1 Pharmaceutical emulsions for retroviral protease inhibitors |
| 01/26/2005 | EP1131062B1 Injectable propofol formulations |
| 01/26/2005 | EP1129723B1 Combined vaccine against both hav and measle virus and method of producing it |
| 01/26/2005 | EP1037604B1 Pharmaceutical aerosol compositions |
| 01/26/2005 | EP1006935B1 High viscosity liquid controlled delivery system |
| 01/26/2005 | EP0942736B1 Use of an estrogen for the prevention and treatment of ischemic damage |
| 01/26/2005 | EP0918498B1 Improved tissue injectable composition |
| 01/26/2005 | EP0871486B1 Diphtheria toxin epitopes |
| 01/26/2005 | EP0820277B1 Powdered pharmaceutical formulations having improved dispersibility |
| 01/26/2005 | EP0706370B2 Use of non-ionic surfactants in stable topical retinoid compositions |
| 01/26/2005 | CN1571817A Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery |
| 01/26/2005 | CN1571794A Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 01/26/2005 | CN1571679A PEG-conjugates of HGF-NK4 |
| 01/26/2005 | CN1571678A Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 01/26/2005 | CN1571666A Freeze-dried pharmaceutical preparation |
| 01/26/2005 | CN1571664A Percutaneous absorption preparations |
| 01/26/2005 | CN1571662A Highly compressible ethylcellulose for tableting |
| 01/26/2005 | CN1571661A Taste masking spill-resistant formulation |
| 01/26/2005 | CN1571660A Solid pharmaceutical agent formulation for a piperazine urea derivative |
| 01/26/2005 | CN1571658A Pharmaceutical formulation comprising (R)-bicalutamide |
| 01/26/2005 | CN1571657A Novel cyclosporin analog microemulsion preconcentrates |
| 01/26/2005 | CN1571655A Heat generating article |